Ignite Creation Date:
2024-05-06 @ 7:52 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06161545
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2023-12-04
Brief Title:
Pembrolizumab N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Stage IV Squamous Cell Carcinoma of the Head and Neck |
| Stage II Squamous Cell Carcinoma of the Head and Neck |
| Stage III Squamous Cell Carcinoma of the Head and Neck |